Page 18 - GPD-3-4
P. 18

Gene & Protein in Disease                                               Human sirtuins (SIRT1-7) in cancer



               Life Sci. 2022;79:297.                             Transl Res. 2022;14(7):4493-4504.
               doi: 10.1007/s00018-022-04342-x                 48.  Jin X, Wei Y, Xu F,  et al. SIRT1 promotes formation of
                                                                  breast cancer through modulating Akt activity.  J  Cancer.
            36.  Tang M, Tang H, Tu B, Zhu WG. SIRT7: A  sentinel of
               genome stability. Open Biol. 2021;11:210047.       2018;9(11):2012-2023.
                                                                  doi: 10.7150/jca.24275
               doi: 10.1098/rsob.210047
                                                               49.  Fang H, Huang Y, Luo Y,  et al. SIRT1 induces the
            37.  Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L.
               Mammalian Sir2 homolog SIRT7 is an activator of RNA   accumulation of TAMs at colorectal cancer tumor sites via
               polymerase I transcription. Genes Dev. 2006;20:1075-1080.  the CXCR4/CXCL12 axis. Cell Immunol. 2022;371:104458.
                                                                  doi: 10.1016/j.cellimm.2021.104458
               doi: 10.1101/gad.1399706
                                                               50.  Guo S, Li F, Liang Y, et al. AIFM2 promotes hepatocellular
            38.  Hubbi  ME, Hu  H,  Kshitiz,  Gilkes DM, Semenza  GL.
               Sirtuin-7 inhibits the activity of hypoxia-inducible factors.   carcinoma metastasis by enhancing mitochondrial
               J Biol Chem. 2013;288:20768-20775.                 biogenesis through activation of SIRT1/PGC-1α signaling.
                                                                  Oncogenesis. 2023;12(1):46.
               doi: 10.1074/jbc.M113.476903
                                                                  doi: 10.1038/s41389-023-00491-1
            39.  Varghese B, Chianese U, Capasso L, et al. SIRT1 activation   51.  Tian WL, Guo R, Wang F, et al. The IRF9-SIRT1-P53 axis is
               promotes energy homeostasis and reprograms liver cancer   involved in the growth of human acute myeloid leukemia.
               metabolism. J Transl Med. 2023;21(1):627.
                                                                  Exp Cell Res. 2018;365(2):185-193.
               doi: 10.1186/s12967-023-04440-9
                                                                  doi: 10.1016/j.yexcr.2018.02.036
            40.  Bosch-Presegué L, Vaquero A. Sirtuin-dependent epigenetic
               regulation in the maintenance of genome integrity. FEBS J.   52.  Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and
               2015;282(9):1745-1767.                             beyond. Biochim Biophys Acta. 2010;1804:1684-1689.
                                                                  doi: 10.1016/j.bbapap.2010.05.002
               doi: 10.1111/febs.13053
                                                               53.  Firestein R, Blander G, Michan S,  et al. The SIRT1
            41.  Betsinger CN, Justice JL, Tyl MD, et al. Sirtuin 2 promotes   deacetylase suppresses intestinal tumorigenesis and colon
               human cytomegalovirus replication by regulating cell cycle
               progression. mSystems. 2023;8(6):e0051023.         cancer growth. PLoS One. 2008;3:e2020.
                                                                  doi: 10.1371/journal.pone.0002020
               doi: 10.1128/msystems.00510-23
                                                               54.  Wang RH, Zheng Y, Kim HS,  et  al. Interplay among
            42.  Polletta L, Vernucci E, Carnevale I, et al. SIRT5 regulation   BRCA1, SIRT1, and Survivin during BRCA1-associated
               of ammonia-induced autophagy and mitophagy. Autophagy.   tumorigenesis. Mol Cell. 2008;32:11-20.
               2015;11(2):253-270.
                                                                  doi: 10.1016/j.molcel.2008.09.011
               doi: 10.1080/15548627.2015.1009778
                                                               55.  Wang RH, Sengupta K, Li C, et al. Impaired DNA damage
            43.  Akter R, Afrose A, Rahman MR,  et al. A  comprehensive
               analysis into the therapeutic application of natural products   response, genome instability, and tumorigenesis in SIRT1
               as SIRT6 modulators in Alzheimer’s disease, aging, cancer,   mutant mice. Cancer Cell. 2008;14(4):312-323.
               inflammation, and diabetes. Int J Mol Sci. 2021;22(8):4180.     doi: 10.1016/j.ccr.2008.09.001
               doi: 10.3390/ijms22084180                       56.  Herranz D, Muñoz-Martin M, Cañamero M,  et al. Sirt1
                                                                  improves healthy ageing and protects from metabolic
            44.  Jaiswal A, Xudong Z, Zhenyu J, Saretzki G. Mitochondrial sirtuins   syndrome-associated cancer. Nat Commun. 2010;1:3.
               in stem cells and cancer. FEBS J. 2022;289(12):3393-3415.
                                                                  doi: 10.1038/ncomms1001
               doi: 10.1111/febs.15879
                                                               57.  Hao C, Zhu PX, Yang X, et al. Overexpression of SIRT1 promotes
            45.  Lee H, Yoon H. Mitochondrial sirtuins: Energy dynamics   metastasis through epithelial-mesenchymal  transition in
               and cancer metabolism. Mol Cells. 2024;47(2):100029.
                                                                  hepatocellular carcinoma. BMC Cancer. 2014;14:978.
               doi: 10.1016/j.mocell.2024.100029
                                                                  doi: 10.1186/1471-2407-14-978
            46.  Shen H, Ma W, Hu Y,  et al. Mitochondrial sirtuins in   58.  Jiang K, Lyu L, Shen Z, et al. Overexpression of SIRT1 is a
               cancer: A revisited review from molecular mechanisms to   poor prognostic factor for advanced colorectal cancer. Chin
               therapeutic strategies. Theranostics. 2024;14(7):2993-3013.
                                                                  Med J (Engl). 2014;127(11):2021-2024.
               doi: 10.7150/thno.97320
                                                               59.  Wang J, Wu J, Wang L, Min X, Chen Z. The LINC00152/miR-
            47.  Wen Y, Huang H, Huang B, Liao X. HSA-miR-34a-5p   138 axis facilitates gastric cancer progression by mediating
               regulates the SIRT1/TP53 axis in prostate cancer.  Am J   SIRT2. J Oncol. 2021;2021:1173869.


            Volume 3 Issue 4 (2024)                         10                              doi: 10.36922/gpd.4100
   13   14   15   16   17   18   19   20   21   22   23